{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrial+Cancers&page=2", "query": { "condition": "Endometrial Cancers", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 854, "total_pages": 86, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrial+Cancers&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrial+Cancers&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T06:46:20.851Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03694262", "title": "The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer", "Uterine Carcinosarcoma" ], "interventions": [ { "name": "Rucaparib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 30, "start_date": "2019-07-19", "completion_date": "2026-03-10", "has_results": true, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-30T06:46:20.851Z", "location_count": 3, "location_summary": "New York, New York • Bethlehem, Pennsylvania • Milwaukee, Wisconsin", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Bethlehem", "state": "Pennsylvania" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03694262" }, { "nct_id": "NCT01806350", "title": "Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cervical Cancer", "Endometrial Cancer", "Ovarian Epithelial Cancer", "Ovarian Germ Cell Tumor", "Uterine Sarcoma", "Vulvar Cancer" ], "interventions": [ { "name": "questionnaire administration", "type": "OTHER" }, { "name": "standard follow-up care", "type": "PROCEDURE" }, { "name": "educational intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "New Mexico Cancer Research Alliance", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "FEMALE", "summary": "30 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2009-11", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2013-03-07", "last_synced_at": "2026-10-30T06:46:20.851Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT01806350" }, { "nct_id": "NCT03665285", "title": "A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumors", "Lung Cancer", "Breast Cancer", "Head and Neck Squamous Cell Carcinoma", "Endometrial Cancer", "Melanoma", "CRC", "Urothelial Carcinoma", "Cholangiocarcinoma" ], "interventions": [ { "name": "NC318", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NextCure, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 109, "start_date": "2018-10-01", "completion_date": "2023-04-11", "has_results": true, "last_update_posted_date": "2024-03-08", "last_synced_at": "2026-10-30T06:46:20.851Z", "location_count": 6, "location_summary": "Los Angeles, California • New Haven, Connecticut • Hackensack, New Jersey + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Gettysburg", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03665285" }, { "nct_id": "NCT07406087", "title": "Navigation Intervention for Adolescent and Young Adult Cancer Survivors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Ovarian Cancer", "Cervical Cancer", "Testicular Cancer", "Colon Rectal Cancer", "Melanoma (Skin Cancer)", "Endometrial Cancer", "Sarcoma", "Thyroid Cancer" ], "interventions": [ { "name": "Adapted patient navigation program targeting adolescent and young adult cancer survivors", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Kaiser Permanente", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "21 Years to 45 Years" }, "enrollment_count": 25, "start_date": "2026-03-15", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-10-30T06:46:20.851Z", "location_count": 1, "location_summary": "Pasadena, California", "locations": [ { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07406087" }, { "nct_id": "NCT03514121", "title": "FPA150 in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Cancer", "Ovarian Cancer", "Endometrial Cancer", "Advanced Solid Tumors" ], "interventions": [ { "name": "FPA150", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Five Prime Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 95, "start_date": "2018-03-27", "completion_date": "2021-04-21", "has_results": true, "last_update_posted_date": "2024-11-22", "last_synced_at": "2026-10-30T06:46:20.851Z", "location_count": 13, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03514121" }, { "nct_id": "NCT06952504", "title": "A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Sacituzumab Tirumotecan", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1123, "start_date": "2025-05-22", "completion_date": "2032-05-24", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-30T06:46:20.851Z", "location_count": 53, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Irvine, California + 47 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Solvang", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06952504" }, { "nct_id": "NCT02269293", "title": "Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 23, "start_date": "2014-10-13", "completion_date": "2021-04-20", "has_results": false, "last_update_posted_date": "2021-04-23", "last_synced_at": "2026-10-30T06:46:20.851Z", "location_count": 3, "location_summary": "Middletown, New Jersey • Harrison, New York • New York, New York", "locations": [ { "city": "Middletown", "state": "New Jersey" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02269293" }, { "nct_id": "NCT07383506", "title": "A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "PIK3CA Mutations", "Advanced Solid Tumors, Adult", "Endometrial Cancer", "HR Positive/HER-2 Negative Breast Cancer", "HER2-low Breast Cancer" ], "interventions": [ { "name": "CGT6297", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cogent Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2026-07-23", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-30T06:46:20.851Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07383506" }, { "nct_id": "NCT02433626", "title": "Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Endometrial Cancer", "Cervical Cancer", "Peritoneal Cancer", "Head and Neck Cancer", "HNSCC", "Colorectal Cancer", "Lung Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "COTI2", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Critical Outcome Technologies Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2015-12", "completion_date": "2020-06", "has_results": false, "last_update_posted_date": "2019-02-01", "last_synced_at": "2026-10-30T06:46:20.851Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02433626" }, { "nct_id": "NCT02575872", "title": "Physical Activity Behavioral Intervention in Obese Endometrial Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage IA Uterine Corpus Cancer", "Stage IB Uterine Corpus Cancer", "Stage II Uterine Corpus Cancer", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC Uterine Corpus Cancer", "Stage IVA Uterine Corpus Cancer", "Stage IVB Uterine Corpus Cancer" ], "interventions": [ { "name": "Exercise Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "FEMALE", "summary": "18 Years to 90 Years · Female only" }, "enrollment_count": 30, "start_date": "2013-10", "completion_date": "2018-06", "has_results": false, "last_update_posted_date": "2019-09-16", "last_synced_at": "2026-10-30T06:46:20.851Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02575872" } ] }